BioAtla Investor Conference Presentation Deck

Focused pipeline with broad applicability of differentiated CAB assets designed to deliver near-term value CAB-ADCs CAB-I/O CAB-Bi- specifics CAB Program BA3011 Mecbotamab Vedotin BA3021 Ozuriftamab Vedotin BA3071 BA3182 Additional programs Target AXL ROR2 CTLA-4 EpCAM & CD3 Various ● ● ● ● Indications STS & Bone Sarcoma NSCLC Ovarian Cancer* NSCLC Melanoma SCCHN Ovarian Cancer* Mutiple tumor types** Adenocarcinoma** Multiple tumor types** Multiple tumor types** IND Enabling Pre-Clinical * Phase 2 investigator-initiated trial for Ovarian Cancer ** Indications based upon tumor target expression bicatla Phase 1 Clinical Phase 2 Clinical IIT, investigator-initiated trial; IND, investigational new drug; NSCLC, Non-small Cell Lung Cancer; RCC, Renal Cell Carcinoma; SCCHN, Squamous Cell Carcinoma of the Head and Neck; STS, Soft Tissue Sarcoma. Anticipated Milestones ✓ Interim sarcoma update Q1 earnings Phase 2 interim NSCLC clinical data Q2 earnings Ovarian IIT dosing 1H22 Phase 2 interim NSCLC and melanoma data mid-year / 2H22 SCCHN trial dosing 1H22 ✓ Ovarian IIT dosing 1H22 Trial dosing 1H22 IND submission and Phase 1 initiation 2022 2023 and beyond BioAtla Overview | Company Confidential 5

View entire presentation